Metagenomi (NASDAQ:MGX) Receives Buy Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of Metagenomi (NASDAQ:MGX) in a research note published on Thursday, Benzinga reports. They currently have a $15.00 price target on the stock.

Several other research analysts also recently commented on the company. BMO Capital Markets reduced their target price on Metagenomi from $22.00 to $17.00 and set an outperform rating for the company in a research note on Thursday, August 15th. HC Wainwright reduced their price objective on shares of Metagenomi from $10.00 to $7.00 and set a buy rating for the company in a research report on Wednesday, August 21st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $15.50.

Metagenomi Trading Up 3.6 %

Metagenomi stock opened at $2.90 on Thursday. The stock has a 50-day simple moving average of $3.82 and a 200 day simple moving average of $6.79. Metagenomi has a 52 week low of $2.63 and a 52 week high of $12.74.

Institutional Trading of Metagenomi

Hedge funds have recently added to or reduced their stakes in the company. Resolute Advisors LLC bought a new position in Metagenomi during the 1st quarter worth $106,000. Vanguard Group Inc. acquired a new position in shares of Metagenomi in the first quarter valued at about $1,894,000. Altitude Crest Partners Inc. bought a new position in Metagenomi during the first quarter worth about $1,407,000. Hhlr Advisors LTD. acquired a new stake in Metagenomi in the 1st quarter worth about $8,205,000. Finally, Artal Group S.A. acquired a new stake in Metagenomi in the 1st quarter worth about $3,165,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.